NCT02797171View on ClinicalTrials.gov

Evaluating the Safety, Pharmacokinetics, and Anti-Viral Activity of VRC01 and VRC01LS in the Serum and Mucosa of Healthy, HIV-Uninfected Adults

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 1, 2017

Primary Completion Date

June 5, 2019

Study Completion Date

June 5, 2019

Conditions

HIV Infections

Interventions

BIOLOGICAL

VRC01

Administered by intravenous (IV) infusion

BIOLOGICAL

VRC01LS

Administered by intravenous (IV) infusion

Trial Locations (4)

7925

Groote Schuur HIV CRS, Cape Town

19104

Penn Prevention CRS, Philadelphia

44106

Case Clinical Research Site, Cleveland

98109-1024

Seattle Vaccine and Prevention CRS, Seattle

All Listed Sponsors

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT02797171 - Evaluating the Safety, Pharmacokinetics, and Anti-Viral Activity of VRC01 and VRC01LS in the Serum and Mucosa of Healthy, HIV-Uninfected Adults | Biotech Hunter | Biotech Hunter